Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Prostatic Neoplasms × xentuzumab × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Docetaxel 249 Prednisone 203 enzalutamide 152 Leuprolide 149 Radiotherapy 141 Abiraterone Acetate 130 Magnetic Resonance Spectroscopy 125 Goserelin 112 bicalutamide 111 Androgen Antagonists 93 Radiosurgery 91 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 89 apalutamide 68 Specimen Handling 62 gallium 68 PSMA-11 61 abiraterone 60 Radiation 50 Gonadotropin-Releasing Hormone 49 darolutamide 48 cabazitaxel 44 Triptorelin Pamoate 44 Brachytherapy 44 pembrolizumab 42 Zoledronic Acid 42 Carboplatin 41 Estramustine 40 Biopsy 40 luprolide acetate gel depot 39 Standard of Care 38 Pluvicto 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05110495 2025-02-17

WINGMEN

University of Oxford

Phase EARLY_PHASE1 Completed

27 enrolled 9 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡